Cingulate (CING) Research & Development (2021 - 2026)
Cingulate's (CING) quarterly Research & Development came in at $2.7 million in Q4 2025, down 37.6% YoY from $4.3 million in Q4 2024, and down 5.18% on a QoQ basis from $2.8 million in Q3 2025.
Cingulate (CING) Research & Development (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Research & Development data on file, last reported at $2.7 million in Q4 2025.
- Quarterly Research & Development fell 37.6% year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.1 million (up 28.11% YoY) and the FY2025 annual result came in at $9.8 million, up 3.48% from the prior year.
- Research & Development retreated to $2.7 million in Q4 2025, from $2.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $5.8 million in Q3 2021 to a low of $562519.0 in Q1 2021.
- A 5-year average of $2.6 million and a median of $2.2 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 391.06% — and 2024, when it plunged 63.59%.
- Tracing CING's Research & Development over 5 years: stood at $1.3 million in 2021, then soared by 52.94% to $1.9 million in 2022, then surged by 158.06% to $5.0 million in 2023, then declined by 13.16% to $4.3 million in 2024, then tumbled by 37.6% to $2.7 million in 2025.
- The last three Research & Development figures came in at $2.7 million (Q4 2025), $2.8 million (Q3 2025), and $2.2 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Cingulate | 70.68 Mn | 70.68 Mn | - | 1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.49 Mn |
| Dec 31, 2025 | 2.70 Mn |
| Sep 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.22 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Dec 31, 2023 | 4.98 Mn |
| Sep 30, 2023 | 3.92 Mn |
| Jun 30, 2023 | 4.46 Mn |
| Mar 31, 2023 | 2.13 Mn |
| Dec 31, 2022 | 1.93 Mn |
| Sep 30, 2022 | 2.12 Mn |
| Jun 30, 2022 | 2.18 Mn |
| Mar 31, 2022 | 2.76 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 5.79 Mn |
| Jun 30, 2021 | 793,587.00 |
| Mar 31, 2021 | 562,519.00 |